Overview

Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors

Status:
Not yet recruiting
Trial end date:
2025-07-03
Target enrollment:
Participant gender:
Summary
Recent studies that ex vivo drug responses on PDO models across different solid tumours can predict treatment responses to chemotherapeutic agents. In patients with metastatic or inoperable solid abdominal tumours, we perform a PDO based drug screen and to identify drugs that will confer clinical response and compared to conventional treatments
Phase:
Phase 2
Details
Lead Sponsor:
Chinese University of Hong Kong